For hematological cancers, enzyme-linked immunosorbent assay (ELISA) or quantitative polymerase chain reaction (qPCR) were used to detect plasma Gal-9 level in the circulating bloodstream. This evidence concerns the gene LGALS9 and hematopoietic and lymphoid cell neoplasm.